EUVIMEDEUVIMED entdecken
Open Access

RNA Expression-Based Analysis to Predict Response in Patients with Metastatic Mismatch Repair Proficient Colorectal Cancer Treated with Regorafenib and Nivolumab

Ruoyu Miao, Dae Won Kim, James Yu, Mokenge Malafa, Rutika Mehta, Jonathan Strosberg, Iman Imanirad, Seema Iyer, Mark Uhlik, Laura Benjamin, Richard Kim

Oncology · 2024

DOI: 10.1159/000535599 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, 2024. Verfasst von Ruoyu Miao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. Hauptthemen laut MEDLINE: Phenylurea Compounds, Pyridines, Colorectal Neoplasms, Nivolumab. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

We previously conducted a phase I/Ib study (NCT03712943) with regorafenib and nivolumab in patients with refractory metastatic mismatch repair proficient (pMMR) colorectal cancer (CRC). This study aimed to investigate the role of Xerna™ TME Panel in predicting the treatment response.

Methods

Twenty-two archival pretreatment tumor samples were subjected to the Xerna™ TME Panel, a machine learning-based RNA-sequencing biomarker assay. The Xerna tumor microenvironment (TME) subtypes were evaluated for correlation with overall survival (OS), progression-free survival (PFS), disease control rate (DCR), and other biomarkers including KRAS, PD-L1, CD8 expression, and Treg cells in TME.

Results

Based on Xerna™ TME Panel, 4 patients with immune-active (IA) subtype and 6 patients with immune-suppressed subtype were classified as biomarker-positive, and five with angiogenic (A) subtype and seven with immune desert subtype were biomarker-negative. While not reaching statistical significance, Xerna TME biomarker-positive patients seemed to have longer median PFS (7.9 vs. 4.1 months, p = 0.254), median OS (15.75 vs. 11.9 months, p = 0.378), and higher DCR (70% vs. 58%, p = 0.675). The IA subtype in our cohort had higher levels of CD4+ FOXP3+ Treg cells, whereas the A subtype showed lower levels of Treg cells.

Conclusion

Xerna™ TME Panel analysis in patients with refractory metastatic pMMR CRC who were treated with regorafenib plus nivolumab might be of value for predictive clinical benefit. Further studies are needed to evaluate the predictive role of Xerna™ TME Panel analysis in patients with refractory metastatic pMMR CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phenylurea CompoundsPyridinesColorectal NeoplasmsNivolumabDNA Mismatch RepairTumor MicroenvironmentAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleMiddle AgedAgedBiomarkers, TumorProgression-Free SurvivalAdultT-Lymphocytes, Regulatory

Stichwörter der Autor:innen

BiomarkerColorectal cancerNivolumabRegorafenibTumor microenvironment

Substanzen

regorafenibPhenylurea CompoundsPyridinesNivolumabBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
  • OncXerna Therapeutics, Inc., Waltham, Massachusetts, USA.

Förderung

  • NCI NIH HHS

Zitieren

APA

Miao, R., Kim, D. W., Yu, J., Malafa, M., Mehta, R., Strosberg, J., Imanirad, I., Iyer, S., Uhlik, M., Benjamin, L., & Kim, R. (2024). RNA Expression-Based Analysis to Predict Response in Patients with Metastatic Mismatch Repair Proficient Colorectal Cancer Treated with Regorafenib and Nivolumab. Oncology. https://doi.org/10.1159/000535599

Vancouver

Miao R, Kim DW, Yu J, Malafa M, Mehta R, Strosberg J, et al. RNA Expression-Based Analysis to Predict Response in Patients with Metastatic Mismatch Repair Proficient Colorectal Cancer Treated with Regorafenib and Nivolumab. Oncology. 2024. doi:10.1159/000535599

BibTeX
@article{Miao2024,
  author = {Miao, Ruoyu and Kim, Dae Won and Yu, James and Malafa, Mokenge and Mehta, Rutika and Strosberg, Jonathan and Imanirad, Iman and Iyer, Seema and Uhlik, Mark and Benjamin, Laura and Kim, Richard},
  title = {RNA Expression-Based Analysis to Predict Response in Patients with Metastatic Mismatch Repair Proficient Colorectal Cancer Treated with Regorafenib and Nivolumab},
  journal = {Oncology},
  year = {2024},
  doi = {10.1159/000535599}
}
Kostenlos starten →